MDT vs REPL · P/E 21, rev $36.36B vs $825.7M cap
Medtronic PLC (MDT) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Medtronic PLC (MDT) is a medical devices company listed on US.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported MDT revenue for 2026-04-24 was $36.36B. Net income was $4.80B. Revenue was up 8.4% from 2025-04-25 to 2026-04-24. MDT currently screens at market cap $100.08B and trailing P/E 20.9.
REPL does not have a complete income-statement cache yet.
MDT currently screens at market cap $100.08B and trailing P/E 20.9. REPL currently screens at market cap $825.7M.
Not investment advice. Open the MDT and REPL stock pages for the full models.
Not investment advice.